Alaunos Therapeutics, Inc.
TCRT
$2.63
-$0.05-1.87%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -160.14% | -20.56% | |||
| Gross Profit | 162.94% | 18.75% | |||
| SG&A Expenses | -16.09% | 1.72% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -34.00% | -1.71% | |||
| Operating Income | 34.35% | 1.37% | |||
| Income Before Tax | 34.16% | 0.18% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 34.16% | 0.18% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 34.16% | 0.18% | |||
| EBIT | 34.35% | 1.37% | |||
| EBITDA | 34.39% | 1.29% | |||
| EPS Basic | 34.16% | 0.18% | |||
| Normalized Basic EPS | 34.17% | 0.18% | |||
| EPS Diluted | 34.16% | 0.18% | |||
| Normalized Diluted EPS | 34.17% | 0.18% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||